Takeda Provides Update on Lung Cancer Program
Takeda will be working with the FDA towards a voluntary withdrawal of EXKIVITY (mobocertinib) in the U.S. and globally where it is currently available.
Related Articles
Antibody-drug conjugates in lung and breast cancer: Current evidence and future directions – a position statement from the ETOP IBCSG Partners Foundation
Following the approval of the first antibody-drug conjugates (ADCs) in the early 2000s, development has increased dramatically, with 14 ADCs now approved and >100 in…
Antibody-drug conjugates in lung and breast cancer: Current evidence and future directions – a position statement from the ETOP IBCSG Partners Foundation
Following the approval of the first antibody-drug conjugates (ADCs) in the early 2000s, development has increased dramatically, with 14 ADCs now approved and >100 in…
Antonio Passaro on LinkedIn: #esmo #sboc
🌎 I am deeply honored to have been a part of the ESMO SUMMIT LATIN AMERICA in Sao Paolo del Brasile 🇧🇷 this past Saturday,…
Bayer receives U.S. FDA Breakthrough Therapy designation for BAY 2927088 for non-small cell lung cancer harboring HER2 activating mutations
BAY 2927088 is an oral, small molecule tyrosine kinase inhibitor under development as a potential new targeted therapy for patients with NSCLC harboring HER2 activating…
Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients – PubMed
Epidermal growth factor receptor (EGFR) exon 20 insertions occur rarely among different cancer types, with the highest frequency reported among non-small-cell lung cancer (NSCLC) patients,…
Amivantamab-Based Regimens Show Anticancer Activity in EGFR-Mutated Advanced NSCLC – The ASCO Post
Widely anticipated findings from the MARIPOSA1 and MARIPOSA-22 trials were presented at the European Society for Medical Oncology (ESMO) Congress 2023, showing potentially improved outcomes…
Takeda announces topline results of phase 3 ADMIRE-CD II trial of Alofisel®
Takeda announces topline results of phase 3 ADMIRE-CD II trial of Alofisel (darvadstrocel) in complex crohn’s perianal fistulas
Takeda Provides Update on Lung Cancer Program
Takeda will be working with the FDA towards a voluntary withdrawal of EXKIVITY (mobocertinib) in the U.S. and globally where it is currently available.
FDA Approves Subcutaneous Administration of ENTYVIO®
Takeda receives FDA approval of subcutaneous ENTYVIO (vedolizumab) for maintenance therapy in adults with moderate to severe ulcerative colitis
Phase 3 MARIPOSA-2 Study Meets Dual Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy With and Without Lazertinib versus Chemotherapy Alone in Patients with EGFR-Mutated Non-S
/PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from the three-arm Phase 3 MARIPOSA-2 study…